(No ratings)
Dr. Steven G. Dubois, MD, MS is a pediatric oncologist in BOSTON, MA specializing in pediatric hematology/oncology. He graduated from University of California, San Francisco (UCSF), School of Medicine. Dr. Steven G. Dubois, MD, MS is affiliated with Dana-Farber Cancer Institute.
Dr. Steven G. Dubois, MD, MS graduated from University of California, San Francisco (UCSF), School of Medicine. He completed residency at University of California, San Francisco (UCSF) Affiliated Hospitals. He is certified by the Board Certification:Pediatric Hematology/Oncology and has a state license in Massachusetts.
Medical School: University of California, San Francisco (UCSF), School of Medicine
Residency: University of California, San Francisco (UCSF) Affiliated Hospitals
Board Certification: Board Certification:Pediatric Hematology/Oncology (2009)
Licensed In: Massachusetts
Dr. Steven G. Dubois, MD, MS does not have any reviews yet, be the first to leave a review of Dr. Steven G. Dubois, MD, MS here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Steven G. Dubois, MD, MS. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| F. Hoffmann-La Roche AG |
$16,420
Non-Covered Product $16,420 |
|
|---|---|---|
| Pfizer Inc. |
$14,680
SUTENT $14,680 |
|
| EMD Serono Research & Development Institute, Inc. |
$6,390
$6,390 |
|
| Bayer HealthCare Pharmaceuticals Inc. |
$5,328
Vitrakvi $5,328 |
|
| Amgen Inc. |
$3,894
$3,894 |
|
| Other |
$3,051
ZEPZELCA $2,880 |
QARZIBA $171 |
| Consulting Fee | $18,492 |
|---|---|
| Travel and Lodging | $15,996 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,680 |
| Food and Beverage | $595 |
Dr. Steven G. Dubois, MD, MS has received 164 research payments totaling $3,581,970.
Dr DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents. His clinical practice focuses on providing outstanding team-based care for children and young adults with solid cancers. He is also a member of the American Pediatric Society.